Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Gustave Roussy today announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and patritumab deruxtecan (U3-1402), two of Daiichi Sankyo’s lead DXd antibody drug conjugates (ADCs), in lung and breast cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200721005963/en/
The collaboration will focus on clinical and translational research, including potential combination strategies for DS-1062, a TROP2 directed DXd ADC, in patients with advanced non-small cell lung cancer (NSCLC), and for patritumab deruxtecan, a HER3 directed DXd ADC, in patients with metastatic breast cancer.
“We look forward to engaging and collaborating with the deep expertise and cutting-edge oncology research capabilities of Gustave Roussy, the premier European Cancer Center, to further advance clinical development of DS-1062 and patritumab deruxtecan,” said Antoine Yver, MD, MSc, AIHP, ACCA Paris, Global Head, Oncology R&D, Daiichi Sankyo. “This innovative research program includes two precision-medicine rich phase 2 trials designed with an adaptive approach to help determine which patients are most likely to benefit from our ADCs with optimal speed and efficiency. Combination therapy strategies will also be explored in other studies.”
“This partnership is strategic for Gustave Roussy and it brings together all the skills which are essential for top quality research in oncology. Launching clinical trials to test two promising molecules in advanced non-small cell lung cancer and metastatic breast cancer is essential for diseases which unfortunately have an increasing incidence and for which there is an urgent need to make progress,” said Prof. Jean-Charles Soria, General Director of Gustave Roussy. "It is by pushing the boundaries of innovation that we will further improve the quality of care for our patients."
About the Collaboration
Under the agreement, Daiichi Sankyo, Inc. will provide funding and support to Gustave Roussy for a comprehensive, integrative research program including clinical, translational and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer, respectively.
Two adaptive phase 2 trials will be conducted, including a multicenter, open-label study to evaluate efficacy, safety and markers of response and resistance to DS-1062 in patients with advanced NSCLC who have progressed on anti-PD-1/PD-L1 therapy and platinum-doublet chemotherapy.
The second multicenter, open-label phase 2 study will evaluate the efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan in patients with HER3 expressing metastatic breast cancer.
Each study will enroll up to 100 patients and will be conducted in several sites in France.
The primary endpoint for both studies is objective response rate as assessed by independent central review. Secondary endpoints include clinical benefit rate, progression-free survival, duration of response, overall survival and safety measures. The studies also will primarily be conducted to analyze biomarker expression and tumor sensitivity; the role of receptor biology in the pharmacological activity of the Daiichi Sankyo DXd ADC platform, as well as factors contributing to treatment resistance; immunogenicity and mechanism of action.
The adaptive trial design includes ongoing clinical and biomarker assessments to identify factors associated with individual patient response and the ability to fine-tune development accordingly.
Additional research to be conducted under the collaboration includes several studies exploring multiple therapeutic combinations for each ADC.
About Gustave Roussy
Gustave Roussy, Europe's leading cancer center, is a global cancer center of expertise entirely dedicated to patients. It brings together 3,100 professionals whose missions are care, research and teaching. The Institute has expertise in the management of rare cancers and complex tumors. It treats all cancers at every stage of life and offers its patients individualized care combining innovation and a humane approach. Twenty-six percent of its new patients are included in clinical trials. For more information, please visit: www.gustaveroussy.fr/en.
About DS-1062 and Patritumab Deruxtecan (U3-1402)
DS-1062 and patritumab deruxtecan (U3-1402) are two of three lead DXd ADCs in the oncology pipeline of Daiichi Sankyo. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.
Designed with Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062 is comprised of a humanized anti-TROP2 monoclonal antibody attached to a topoisomerase I inhibitor payload by a tetrapeptide-based linker. Patritumab deruxtecan is comprised of a human anti-HER3 antibody and the same payload and linker as DS-1062.
DS-1062 is currently being evaluated in a phase 1 trial in patients with advanced solid tumors that are refractory to or relapsed from standard treatment or for whom no standard treatment is available. The study is currently enrolling patients with unresectable advanced NSCLC and unresectable/advanced or metastatic triple negative breast cancer.
Patritumab deruxtecan is currently being evaluated in a phase 1 study in previously treated patients with metastatic or unresectable NSCLC. Patritumab deruxtecan is also being evaluated in a phase 1/2 study in patients with HER3 expressing metastatic breast cancer.
DS-1062 and patritumab deruxtecan are investigational agents that have not been approved for any indication in any country. Safety and efficacy have not been established.
About Daiichi Sankyo Cancer Enterprise
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc.
+1 908 992 6631 (office)
+1 201 709 9309 (mobile)
Daiichi Sankyo Europe GmbH
+49 (89) 7808751 (office)
+49 176 11780861 (mobile)
Daiichi Sankyo Co., Ltd.
+81 3 6225 1126 (office)
Investor Relations Contact:
+33 1 42 11 50 59 (office)
+33 6 17 66 00 26 (mobile)
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BAT Highlights Serious Inaccuracies in EU e-Cigarette Review29.10.2020 10:56:00 CET | Press release
BAT has called on a European Commission scientific committee to enhance the quality of its ongoing review into e-cigarettes. BAT highlighted several serious flaws, the details of which it makes public today. The results of the review may pave the way for revisions to rules that affect millions of vapers across the EU. The SCHEER Committee (Scientific Committee on Health, Environmental and Emerging Risks) is an advisory body that was tasked with producing a scientific review of the health effects of e-cigarettes as part of the European Commission’s forthcoming review of the Tobacco Products Directive. The consultation period for this review has now closed. BAT’s response highlights major flaws with the methodology and conclusions of the review including that it: Fails to contextualize the risks of e-cigarettes relative to those associated with continued smoking. Makes inaccurate claims regarding e-cigarettes many of which have been widely debunked by the scientific and public health com
Icon Solutions Secures Strategic Investment From J.P. Morgan29.10.2020 10:15:00 CET | Press release
Icon Solutions, the specialist provider of world-class payment solutions and consultancy services, today announced a strategic investment from J.P. Morgan. Icon Solutions is a leading global provider of payments technology and expertise, with a proven track record developing, implementing and running innovative, mission critical transaction banking solutions. Icon has also defined, architected and built IPF: a cloud native, highly cost-effective and collaborative payments platform that combines open source technology with light-weight integration. “We’re excited to support Icon with this strategic investment as they look to continually build a simplified, collaborative payments ecosystem, driving emerging payments rails and innovation,” said Sara Castelhano, EMEA Head of Payments, Digital and Solutions, J.P. Morgan Wholesale Payments. Icon will invest in its technology and geographic reach, helping new and existing customers do more with less and realise the potential of payments in th
Airship Journeys Powers Massive Conversion Gains for Brands Across the Globe29.10.2020 09:30:00 CET | Press release
Customer engagement company Airship today detailed the amazing success three brand marketers have achieved using Airship Journeys to more quickly and easily improve the business impact of cross-channel customer journeys. The customer journeys these marketers have optimized have driven double- and even triple-digit percentage performance improvements over baselines established by control groups. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005340/en/ Airship Journeys enables an at-a-glance understanding of how cross-channel journeys are performing against business goals, trending performance lifts against control group baselines to direct optimization efforts and maximize business value. (Graphic: Business Wire) Airship Journeys combines everything marketers need to create, evaluate, test and optimize cross-channel customer engagement journeys in a single, intuitive visual UI. Only Airship Journeys allows marketers to
Realtek Semiconductor Selects Allegro DVT’s H.266/VVC Compliance Streams29.10.2020 08:57:00 CET | Press release
Allegro DVT, the leading provider of video codec compliance test suites and semiconductor video IPs, today announced that Realtek Semiconductor, one of the world's largest and most successful fabless semiconductor companies, has selected Allegro DVT’s VVC test streams and will be used to ensure compliance of Realtek’s products with the new emerging VVC video compression standard. Versatile Video Coding (VVC) is the latest video compression standard that was finalized in June 2020. The VVC codec has been conceived to be versatile and to address all video applications such as mobile telephony, VOD, Broadcasting, OTT streaming, videoconferencing, screen content, 360° and scalable coding and their requirements in terms of resolution, bitrates and latency. The Allegro DVT VVC test suite enables comprehensive coverage and verification of VVC decoders and ensures that decoders are fully compliant with all corner cases of the VVC specification. Furthermore, this VVC test suite is part of a bro
SES and CANAL+ Strengthen Partnership With Long-Term Extensions across Western Europe, Central Europe and Africa29.10.2020 08:50:00 CET | Press release
SES and CANAL+ have signed new long-term strategic agreements for satellite capacity across three geographies, strengthening the companies’ longstanding partnership and underlining the importance of satellite in delivering premium content to more than 10 million subscribers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005375/en/ SES and CANAL+ Strengthen Partnership With Long-Term Extensions across Western Europe, Central Europe and Africa (Photo: Business Wire) The multi-transponder contract renewal extends SES and CANAL+ relationship to the end of the decade. It enables SES to support the French pay-TV operator in broadcasting its high-quality bouquets to millions of households around the world via 19.2 degrees East, 23.5 degrees East and 22 degrees West. The new contract represents additional secured backlog of over EUR 230 million and includes options for additional capacity and extensions. Partners with SES sin
Thales Launches Its Identity Verification Suite, a Secure Biometric Solution for Customer Onboarding29.10.2020 08:00:00 CET | Press release
Thales, world leader in digital security, has launched its Identity Verification Suite, in response to the rising need of remote client onboarding. With privacy and user experience as its heart, the IDV Suite enables a secure and 100%-AI identity verification service. It integrates the latest facial recognition technology, document security features recognition and machine learning engines. The solution addresses the Covid-19 environment with touchless interactions, allowing service providers to reach end users via their mobile handsets or the web. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005392/en/ (Photo: Thales) Secure identity verification has become a crucial part of online security and digital onboarding, and constitutes a significant opportunity for businesses. In cases such as digital enrolment or KYC (Know Your Customer) regulations, ID verification is critical in order to efficiently detect fraud and th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom